



# RITUXAN MEDICATION ORDER

Patient's Name (Last, First, Middle) \_\_\_\_\_ DOB \_\_\_\_\_

Patient's height in feet and inches \_\_\_\_\_ Patient's weight in pounds \_\_\_\_\_

### ■ Diagnosis

Diagnosis and the most specific ICD-10 code available: \_\_\_\_\_

### ■ Details Needed for Approval

#### Rheumatoid Arthritis

- Has the patient had a failure, contraindication or allergy to Truxima or Ruxience? \_\_\_\_\_
- Has the patient been diagnosed with moderate-to-severe active RA? \_\_\_\_\_
- Is Rituximab being used with methotrexate? \_\_\_\_\_ If not, is there a contraindication/intolerance? \_\_\_\_\_
- Has the patient tried and failed at least a 3 month trial of methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine? \_\_\_\_\_ If not, is there an intolerance or contraindication to all conventional agents? \_\_\_\_\_
- Has the patient tried another biological immunomodulator agent FDA labeled or compendia supported for RA? \_\_\_\_\_
- Has the patient been treated with Rituximab in the past 16 weeks? \_\_\_\_\_
- Please provide us with detailed notes on disease status, progression, prognosis, past meds and a full history.

#### Pemphigus Vulgaris

- Has the patient had a failure, contraindication or allergy to Truxima or Ruxience? \_\_\_\_\_
- Has the patient been diagnosed with moderate-to-severe PV? \_\_\_\_\_
- Check off all clinical signs exhibited:
  - Lesions/Erosions/Blisters
  - Nikolsky sign
  - Characteristic scarring and lesion distribution
- Include written report of Histopathologic confirmation by skin/mucous membrane biopsy.
- Include results demonstrating presence of autoantibodies as detected by direct or indirect immunofluorescence.
- Have you ruled out other causes of blistering or erosive skin and mucous membrane diseases? \_\_\_\_\_

### ■ Premedication Order

Oral medications to be taken by the patient at least 60 minutes prior to start of infusion treatment. May be taken at home:

- Acetaminophen \_\_\_\_\_mg       Diphenhydramine \_\_\_\_\_mg       Cetirizine 10mg

IV medications to be administered prior to start of the infusion treatment:

- Dexamethasone \_\_\_\_\_mg       Famotidine \_\_\_\_\_mg  
 Diphenhydramine \_\_\_\_\_mg       Methylprednisolone \_\_\_\_\_mg

### ■ Rituxan (rituximab) Intravenous Order

Dose: \_\_\_\_\_ mg/kg

#### Rate:

- \_\_\_\_\_ ml over \_\_\_\_\_ minutes  
 Start at \_\_\_\_\_ ml/hr, after \_\_\_\_\_ minutes increase to \_\_\_\_\_ ml/hr, after \_\_\_\_\_ minutes increase to \_\_\_\_\_ ml/hr

#### Volume:

- \_\_\_\_\_ ml of normal saline       \_\_\_\_\_ ml of half normal saline       \_\_\_\_\_ ml of D5W

Frequency: To be administered every \_\_\_\_\_ for \_\_\_\_\_. (Ex: every 2 days for 3 weeks)

After the infusion is complete, flush with normal saline. Check vitals and monitor for signs and symptoms of an infusion reaction at start, throughout infusion, and after completion.

Patient's Name (Last, First, Middle) \_\_\_\_\_

DOB \_\_\_\_\_

**■ Rescue Management in case of Infusion Therapy Reaction**

*These include fever, chills, rigors, headache, rash, itching, swelling, edema, nausea, vomiting, abdominal pain, hypotension, and respiratory distress.*

- Stop medication infusion and start normal saline infusion at 50 ml/hr. Call ordering provider to report reaction.
- Diphenhydramine 50mg IV and Methylprednisolone 125mg IV for allergic reactions.
- Albuterol sulfate 2.5ml by nebulizer for wheezing and respiratory reactions. Provide oxygen as needed.
- Famotidine 20mg IVP for minor cutaneous reactions which do not respond to diphenhydramine.
- For severe reactions, administer Epi-pen or equivalent and call 911. Repeat if severe symptoms persist.

**■ Documentation to Include**

- Patient demographics and insurance, including allergies and including card scans (both medical and pharmacy benefit cards, both sides).
- Most recent chart notes and, if available, last history and physical.
- All relevant scans, tests and laboratory results (including CBC with platelet, quantitative immunoglobulins, Hepatitis B antigen, Hepatitis B core total antibody and QuantiFERON gold).
- If this is a new medication for the patient, chart notes which include decision to begin treatment. If the patient is already being treated on this therapy, provide last treatment date and notes.

**■ Ordering Provider Authorization**

Provider Signature: \_\_\_\_\_ Name: \_\_\_\_\_ Date: \_\_\_\_\_

Address: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Indiv. NPI #: \_\_\_\_\_ License: \_\_\_\_\_

Best Contact Person in Office: \_\_\_\_\_ Direct Phone to Contact Person: \_\_\_\_\_

**FAX THIS ORDER AND SUPPORTING DOCUMENTATION TO 201-266-0437 OR UPLOAD USING YOUR SECURE DEDICATED WEBPAGE – TO GET A PERSONAL LINK PLEASE CONTACT THE INTAKE TEAM.**